Nyxoah

Nyxoah SA has appointed Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. Kelly brings more than 25 years of leadership experience, having served as Chairman, President and Chief Executive Officer of Teleflex Incorporated until January 2026, after leading that company as President and Chief Executive Officer from January 2018 and as Chairman of the Board from May 2020. The appointment reflects Nyxoah's continued evolution into a U.S.-focused commercial organization following FDA approval and the launch of Genio in the United States. Chairman Robert Taub said Kelly is a seasoned U.S. MedTech executive with a strong track record of scaling organizations, driving commercial performance and creating shareholder value, and thanked Olivier Taelman for his leadership over the past seven years in bringing Nyxoah from clinical development through FDA approval and into U.S. commercialization. Kelly said Genio is a truly differentiated technology in the treatment of sleep apnea, that the U.S. launch is still in its early stages, and that he looks forward to scaling the business and bringing Genio to many more OSA patients.

Nyxoah has received $15 million from the European Investment Bank as the second tranche of its loan facility. The drawdown follows confirmation that the company met predefined criteria, and brings total new capital raised in June 2026 to approximately $110 million when combined with the proceeds of its recent underwritten public offering. The non-dilutive funding will primarily accelerate the commercial launch of the Genio system in the United States, while also supporting research and development and manufacturing scale-up. CEO Olivier Taelman called the financing transformative and a strong endorsement of the company's technology.